Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03205995 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome
A Phase 3 study, sponsored by Omeros Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 6
- Enrollment target
NCT03205995 is a Phase 3 study that was terminated before completion, run by Omeros Corporation. The registered enrollment target is 6 participants.
The verdict
NCT03205995, a Phase 3 study, was terminated before completion, sponsored by Omeros Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the platelet count change from baseline and safety of OMS721 (narsoplimab) in adults and adolescents with atypical hemolytic uremic syndrome (aHUS). The study will also evaluate pharmacokinetics (PK), pharmacodynamics (PD), and anti-drug antibody response (ADA).
Interventions
- BIOLOGICAL OMS721 (narsoplimab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-05-02 |
| Est. Completion | 2021-02-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03205995
The ClinicalTrials.gov registry entry for NCT03205995 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Omeros Corporation, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OMS721 (narsoplimab) is the first listed.
NCT03205995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03205995 about?
NCT03205995 is a clinical study titled "Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome". The purpose of this study is to evaluate the platelet count change from baseline and safety of OMS721 (narsoplimab) in adults and adolescents with atypical hemolytic uremic syndrome (aHUS). The study will also evaluate pharmacokinetics (PK), pharmacodynamics (PD), and anti-drug antibody response (AD...
What is the current status of trial NCT03205995?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 6 participants. The study started on 2018-05-02. Estimated completion is 2021-02-02.
What interventions are being tested in trial NCT03205995?
The interventions under investigation include: OMS721 (narsoplimab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03205995?
This trial is sponsored by Omeros Corporation, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.